Cancer Family
Malignant Skin Neoplasm
CI-CAN-00000250Explore in graph →
320 active trials14 approved drugs64 evidence items
- NCIt
- C2920
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000250Explore in graph →
Clinical trials
1,248 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (202)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06990737 | Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 0 | Aug 31, 2026 | clinicaltrials |
| NCT07100925 | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Ankyra Therapeutics, IncINDUSTRY | 0 | Jun 25, 2026 |
| clinicaltrials |
| NCT02943642 | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides(Resimmune®) | withdrawn | Phase 2 | 0 | Virogen Biotechnology Inc.INDUSTRY | 0 | May 18, 2026 | clinicaltrials |
| NCT04064424 | Cancer Prevention & Online Technologies | withdrawn | N/A | 0 | Stanford UniversityOTHER | 0 | Apr 20, 2026 | clinicaltrials |
| NCT05846724 | Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma(PULSAR) | withdrawn | Phase 2 | 0 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 0 | Jan 22, 2026 | clinicaltrials |
| NCT05538988 | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma(BIOSELECT) | withdrawn | Phase 1 / Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05106192 | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04099446 | A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer | withdrawn | — | 0 | ProgenaBiomeOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT04329221 | Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT04642287 | Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02548468 | Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT06644079 | Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT03288818 | Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06207786 | Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery | withdrawn | N/A | 0 | Mayo ClinicOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06638736 | A Randomized Controlled Trial Comparing Sutures vs Staples for High Tension Closures | withdrawn | N/A | 0 | University of Kansas Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03327064 | A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Alabama at BirminghamOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | withdrawn | Phase 2 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jul 26, 2024 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05643755 | Preoperative Image-based Education Effect on Postoperative Satisfaction of Patients Undergoing First-time Dermatologic Surgery | withdrawn | N/A | 0 | Johns Hopkins UniversityOTHER | 0 | Apr 8, 2024 | clinicaltrials |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04176900 | 3D Printed Rigid Bolus Versus Silicone Bolus for Treatment of Tumors Involving the Skin: A Comparative Study | withdrawn | N/A | 0 | Nova Scotia Cancer CentreOTHER | 0 | Oct 2, 2023 | clinicaltrials |
| NCT05729139 | Cemiplimab/Peg-Interferon-α in Advanced CSCC | withdrawn | Phase 1 | 0 | Baptist Health South FloridaOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT04252612 | Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study | withdrawn | Early Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | withdrawn | Phase 1 | 0 | Rakuten Medical, Inc.INDUSTRY | 0 | Apr 19, 2023 | clinicaltrials |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Nov 18, 2022 | clinicaltrials |
| NCT04127318 | Low-moderate Intensity Pedaling During Immunotherapy Administration | withdrawn | N/A | 0 | Rush University Medical CenterOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT04985825 | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma(I-PACE) | withdrawn | Phase 2 | 0 | Pega-One S.A.S.INDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT02301494 | Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma(CTCL) | withdrawn | N/A | 0 | Rochester General HospitalOTHER | 0 | Apr 27, 2021 | clinicaltrials |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma(Pelican) | withdrawn | Phase 1 | 0 | Turnstone Biologics, Corp.INDUSTRY | 0 | Apr 6, 2021 | clinicaltrials |
| NCT02867722 | Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States(DaylightPDT) | withdrawn | N/A | 0 | Brigham and Women's HospitalOTHER | 0 | Feb 1, 2021 | clinicaltrials |
| NCT02699723 | Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer | withdrawn | Early Phase 1 | 0 | Jean Yuh TangOTHER | 0 | Oct 22, 2020 | clinicaltrials |
| NCT03617224 | Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome | withdrawn | Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT04117373 | Mohs Micrographic Surgery and Reconstruction in the Optum Insurance Claims Database | withdrawn | — | 0 | University of PennsylvaniaOTHER | 1 | Mar 6, 2020 | clinicaltrials |
| NCT03548610 | Efficacy and Safety of a Nanofat-seeded Biological Scaffold in Healing Lower Limb Surgical Defects | withdrawn | N/A | 0 | Brigham and Women's HospitalOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT01385943 | VivaNet Study. A Multicenter Study of Confocal Reflectance Microscopy in Telemedicine(EUNET) | withdrawn | — | 0 | Lucid, Inc.INDUSTRY | 2 | Nov 8, 2019 | clinicaltrials |
| NCT03757663 | UV Dosimetry Feedback in NMSC Patients | withdrawn | N/A | 0 | University of Colorado, DenverOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT03373305 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT01060319 | A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies | withdrawn | — | 0 | Stanford UniversityOTHER | 1 | Apr 18, 2019 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT03282188 | REO13 Melanoma With of Without GM-CSF | withdrawn | Phase 1 / Phase 2 | 0 | University of LeedsOTHER | 0 | May 4, 2018 | clinicaltrials |
| NCT02812693 | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | withdrawn | Phase 1 / Phase 2 | 0 | Joanne JeterOTHER | 0 | Apr 5, 2018 | clinicaltrials |
| NCT03235869 | Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma | withdrawn | Early Phase 1 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT02321982 | Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery | withdrawn | N/A | 0 | Dartmouth-Hitchcock Medical CenterOTHER | 0 | Jul 6, 2017 | clinicaltrials |
| NCT00226993 | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. | withdrawn | Phase 1 / Phase 2 | 0 | Stanford UniversityOTHER | 0 | Dec 1, 2016 | clinicaltrials |
| NCT02757248 | Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL | withdrawn | Phase 1 | 0 | Anne Beaven, MDOTHER | 0 | Dec 1, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT02061007 | Biomarker Correlates of Hypoxia in Metastatic Melanoma | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | May 9, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Aug 31, 2026source: clinicaltrials